8-week triple DAA combo cures most people with genotype 1-6 hepatitis C
AbbVie pangenotypic combination cures 98% or above across genotypes
AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3
US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C
Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients
Liver cancer risk reduced after hepatitis C treatment, but vigilance needed for aggressive cancers in months after treatment
Real-world responses to HCV treatment among US veterans match best clinical trial results
Generic hepatitis C drugs purchased online achieve high cure rates
New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment
